AnaptysBio, Inc.
NASDAQAnaptysBio enters the post-earnings session as a stock at war with itself — fresh evidence of commercial weakness on one side, a chorus of analysts lifting targets on the other. Q1 results released Tuesday evening were the catalyst. The company posted EPS of -$1.84 against a consensus expectation of around -$0.75, while sales of $25.6 million fell short of the $29 million the…
Snapshot as of 13 May 2026
AnaptysBio enters the post-earnings session as a stock at war with itself — fresh evidence of commercial weakness on one side, a chorus of analysts lifting targets on the other. Q1 results released Tuesday evening were…
AnaptysBio reports Q1 results on May 15 with short sellers quietly adding pressure just as the stock trades near its lowest level in months. The short interest angle is the standout setup heading into this print. Bears…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ANAB — free to start on ORTEX.
Sign up for free →Open ANAB on ORTEX